Iambic Therapeutics (IAM) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iambic Therapeutics is the larger company by market cap ($621.4 million vs $596.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IAM | SRZN |
|---|---|---|
| Share price | $13.11 | $28.46 |
| Market cap | $621.42M | $596.40M |
| 1-day change | -8.06% | -7.21% |
| YTD return | — | +25.93% |
| 1-year return | — | +115.61% |
| 5-year return | — | -78.97% |
| EPS (TTM) | $-2.69 | $-41.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.48M |
| Revenue growth (YoY) | — | -67.37% |
| Net income (latest FY) | — | $-242.03M |
| Operating margin | — | -1210.58% |
| Net margin | — | -6960.77% |
| 52-week high | $25.00 | $37.83 |
| 52-week low | $9.60 | $12.79 |
| Distance from 52-week high | -47.56% | -24.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +107.86% | +123.12% |
| Average volume | 714.92K | 537.16K |
| Shares outstanding | 47.40M | 20.96M |
| Employees | 171 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Iambic Therapeutics
IAM stock →Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
IAM vs SRZN FAQ
Which is bigger, Iambic Therapeutics or Surrozen?
Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $596.40M for Surrozen (SRZN).
Are Iambic Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.